06.17.21
Ingredient supplier OmniActive Heatlh Technologies recently presented four published studies providing clinical substantiation for four of its ingredients in the weight management, eye health, energy, and cognition categories at last week’s American Society of Nutrition conference, which were each published in the journal Current Developments in Nutrition.
“We are dedicated to propelling our industry with strong research to further solidify the efficacy and safety of our offerings,” Deshanie Rai, PhD, VP, Global Scientific & Regulatory Affairs for OmniActive, said. “We are pleased at how well each of these clinicals was received by the scientific community, as well as the attention from the industry we are gaining because of them. These four posters represent our continued efforts to build a robust breadth of science to substantiate our position within the categories we specialize in.”
The first study, on the pharmacokinetics of sustained-release caffeine supplement Xtenergy, concluded that the supplement offered a slow and sustained level of plasma caffeine, and that among 26 participants, supplementation of 200 mg daily was associated with feelings of being more alert, less tired, better overall mood, less jittery, and less tense for longer time periods, based on self-reported changes. The authors of the study said that a sustained release caffeine formulation like Xtenergy could be beneficial for those involved in sustained activities demanding peak cognitive and physical performance for longer periods of time.
The second study focused on Capsimax, a supplement containing extracted capsaicinoids from red chili peppers, and its potential ability to beneficially modulate resting energy expenditure (REE). Energy expenditure plays an important role in obesity development, hence an increase in REE could facilitate body weight management, since REE represents 60% of total energy expenditure in most people. In 17 males and 7 females who participated in the placebo-controlled, double-blind, crossover study, supplementation significantly increased changes in REE at one hour, two hours, three hours, and four hours post-supplementation in males. These findings were consistent with a previous study, called the Metabolic Rate 1 study.
OmniActive is currently expanding its eye health and performance portfolio, and began a clinical program on a new blend of integrated active ingredients formulated to address dry eye discomfort. The study on a novel multi-ingredient formulation which contained lutein, zeaxanthin, curcuminoids, and vitamin D3 in the form of a capsule concluded that in 30 subjects in the test group (compared to 29 placebo participants), supplementation resulted in significant improvements in tear volume, tear film break up time, and reduction in self-reported dry eye symptoms. The authors concluded that this nutritional combination, which will see a commercial launch later in the year, improved eye hydration and moisture, tear stability and quality, and overall eye comfort.
OmniActive also conducted a bioavailability study on a custom lutein and zeaxanthin ingredient, which was developed to deliver these ingredients in a more bioavailable form. The formula, the researchers concluded, could be advantageous for consumers looking to quickly improve their lutein and zeaxanthin status, potentially enhancing their vision protection and performance. The study involved 90 healthy volunteers, who were administered either the novel formulation or a reference product, each of which respectively contained 10 mg of lutein and 2 mg of zeaxanthin, and it was found that the group who took the new product had 2-fold and 1.5-fold greater absorption of lutein and zeaxanthin levels, respectively, and the end of a single dose.
“OmniActive prides itself on being a partner of choice for customers seeking to differentiate with innovative and clinically validated ingredients,” Kimberly Smith, CMO at OmniActive, said. “It’s not just about providing a premium ingredient – it’s about listening to the needs of our customers and working closely together with them to deliver a solution that helps them grow their business.”
“We are dedicated to propelling our industry with strong research to further solidify the efficacy and safety of our offerings,” Deshanie Rai, PhD, VP, Global Scientific & Regulatory Affairs for OmniActive, said. “We are pleased at how well each of these clinicals was received by the scientific community, as well as the attention from the industry we are gaining because of them. These four posters represent our continued efforts to build a robust breadth of science to substantiate our position within the categories we specialize in.”
The first study, on the pharmacokinetics of sustained-release caffeine supplement Xtenergy, concluded that the supplement offered a slow and sustained level of plasma caffeine, and that among 26 participants, supplementation of 200 mg daily was associated with feelings of being more alert, less tired, better overall mood, less jittery, and less tense for longer time periods, based on self-reported changes. The authors of the study said that a sustained release caffeine formulation like Xtenergy could be beneficial for those involved in sustained activities demanding peak cognitive and physical performance for longer periods of time.
The second study focused on Capsimax, a supplement containing extracted capsaicinoids from red chili peppers, and its potential ability to beneficially modulate resting energy expenditure (REE). Energy expenditure plays an important role in obesity development, hence an increase in REE could facilitate body weight management, since REE represents 60% of total energy expenditure in most people. In 17 males and 7 females who participated in the placebo-controlled, double-blind, crossover study, supplementation significantly increased changes in REE at one hour, two hours, three hours, and four hours post-supplementation in males. These findings were consistent with a previous study, called the Metabolic Rate 1 study.
OmniActive is currently expanding its eye health and performance portfolio, and began a clinical program on a new blend of integrated active ingredients formulated to address dry eye discomfort. The study on a novel multi-ingredient formulation which contained lutein, zeaxanthin, curcuminoids, and vitamin D3 in the form of a capsule concluded that in 30 subjects in the test group (compared to 29 placebo participants), supplementation resulted in significant improvements in tear volume, tear film break up time, and reduction in self-reported dry eye symptoms. The authors concluded that this nutritional combination, which will see a commercial launch later in the year, improved eye hydration and moisture, tear stability and quality, and overall eye comfort.
OmniActive also conducted a bioavailability study on a custom lutein and zeaxanthin ingredient, which was developed to deliver these ingredients in a more bioavailable form. The formula, the researchers concluded, could be advantageous for consumers looking to quickly improve their lutein and zeaxanthin status, potentially enhancing their vision protection and performance. The study involved 90 healthy volunteers, who were administered either the novel formulation or a reference product, each of which respectively contained 10 mg of lutein and 2 mg of zeaxanthin, and it was found that the group who took the new product had 2-fold and 1.5-fold greater absorption of lutein and zeaxanthin levels, respectively, and the end of a single dose.
“OmniActive prides itself on being a partner of choice for customers seeking to differentiate with innovative and clinically validated ingredients,” Kimberly Smith, CMO at OmniActive, said. “It’s not just about providing a premium ingredient – it’s about listening to the needs of our customers and working closely together with them to deliver a solution that helps them grow their business.”
